Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

August 31, 2017

Conditions
Chronic Kidney DiseaseType 2 Diabetes
Interventions
BIOLOGICAL

Neo-Kidney Augment

NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.

Trial Locations (1)

27599

University of North Carolina- Chapel Hill, Chapel Hill

Sponsors
All Listed Sponsors
collaborator

CTI Clinical Trial and Consulting Services

OTHER

lead

Prokidney

INDUSTRY